Expanded Access Programs (EAPs) are intended to give patients access to investigational drugs to treat serious or life-threatening diseases or conditions for which there are no adequate therapies available.
Satraplatin will be given to patients free of charge under the SPERA program.
Satraplatin is GPC Biotech’s investigational orally bioavailable drug for the treatment of hormone-refractory prostate cancer.
Physicians in the U.S. can contact 1-800-349-8086 for more information on SPERA.
Find more details from the full report.
Comment Preview